Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @murphey_richard
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @murphey_richard
-
"The proportion of new [FDA] approvals supported by at least 2 pivotal trials decreased from 80.6% in 1995-1997 to 52.8% in 2015-2017"https://twitter.com/AlecGaffney/status/1217181650871836674 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Source of all this is PRs / SEC filings / websites, any corrections are welcome!
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
M&A exits were roughly in line with 2018. Biggest buyouts of VC-backed biopharma companies: Lilly / Loxo, $8B Roche / Spark, $4.8B Astellas / Audentes, $3B Sanofi / Synthorx, $2.5B UCB / Dova, $2.5B Ipsen / Clementia, $1.3B Merck / Peloton, $1B upfront / $2.2B total
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Here's a table with all of the VC-backed biopharma IPOs on NASDAQ / NYSE in 2018 and 2019 that raised $50M+ https://www.baybridgebio.com/biotech-ipos.html …pic.twitter.com/H56HomOgEE
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
VC backed biopharma IPOs are down a bit, but 2019 was still a good year (this only includes VC-backed biopharma IPOs that raised $50M+) https://www.baybridgebio.com/startup_database.html …pic.twitter.com/hdIvp7nEYa
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Cancer still dominates, but neuro + neurodegenerative is the second biggest category. Rare disease is 3rd.pic.twitter.com/4WYZD6A0iW
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The Series B landscape has changed as well. Most notably, Chinese investors aren't leading deals in US companies. https://www.baybridgebio.com/blog/top_vcs_2018.html …pic.twitter.com/VrJlgQopFw
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The most active Series A investors have changed from 2018 to 2019. By my count, ARCH, Canaan, and Sofinnova led the most Series A deals in 2019 (this is just based on PRs, stealth co's not counted) https://www.baybridgebio.com/blog/top_vcs_2018.html …pic.twitter.com/tSQgLPs9FG
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Quick pre-JPM recap of biotech startup funding and exits in 2019: venture funding of biopharma down modestly in 2019 from 2018. Series A down a bit, Series B up a bit https://www.baybridgebio.com/startup_database.html …pic.twitter.com/VXmVnchVaM
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
If you want to learn more, read Sally Smith Hughes' book Genentech: The Beginnings of Biotech. It's a quick and engaging read. You can also check out an article I wrote with a bit more context on the above quotes:https://www.baybridgebio.com/blog/lessons-from-genentech.html …
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
All of the quotes above are from Sally Smith Hughes' interviews from Berkeley's Bancroft Library Oral History Center. https://bancroft.berkeley.edu/ROHO/projects/biosci/oh_list.html …
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
But perhaps the most important thing Bob brought to Genentech was his determination, optimism and ability to get things done. Those traits more than made up for his lack of experience.pic.twitter.com/1Ic3HOC2gt
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Genentech's focus on capital efficiency was another key tactic that reduced financing risk and let them stay independent.pic.twitter.com/WO9NKuaM0Y
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today the idea of a profitable biopharma startup almost seems ridiculous. It is incredible that Bob had profitability as a goal -- and achieved it. Perhaps that's why Genentech was able to survive as an independent company for so long.
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Financing risk is always huge for pre-revenue biopharma companies, especially for those that want to sell their own products. Bob was acutely aware of this and focused on profitability. He partnered non-core assets to fund work on core products.pic.twitter.com/xRSnK8Ix2w
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Genentech's goal was always to develop and sell their own products, rather than just licensing projects to pharma. The value of a drug increases exponentially as it advances through the development process.pic.twitter.com/XAemzvA2h7
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The only downside of insulin as an initial product was that Genentech couldn't market it themselves. They had to partner with a big company for commercialization. For startups, low-prevalence indications with high unmet need > highly prevalent indicationspic.twitter.com/0U07yBSpeC
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The short path to human proof of concept for insulin was also attractive: short studies, objective endpoints, and an approvable biomarker endpoint with high correlation to clinical outcomes.pic.twitter.com/5Tl0A2W8YV
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Another benefit of insulin as an initial product was that insulin was known to improve clinical outcomes for people with diabetes. Low clinical risk + best-in-class product = great initial indication for new techpic.twitter.com/KQ9aCcopIG
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.